Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The pharmacokinetic profile of fesoterodine 8 mg with daytime or nighttime dosing.

European journal of clinical pharmacology - 1 Feb 2010

Malhotra Bimal K, Crownover Penelope H, LaBadie Robert, Glue Paul, MacDiarmid Scott A

Abstract excerpt

PURPOSE: Diurnal variation can affect drug pharmacokinetics. Fesoterodine is a new antimuscarinic drug for the treatment of overactive bladder (OAB). We estimated the relative bioavailability of 5-hydroxymethyl tolterodine (5-HMT), the active metabolite of fesoterodine, following nighttime and da...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzhydryl Compounds
Share to Biological Availability
Share to Cresols

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cross-Over Studies

Share to Delayed-Action Preparations

Share to Half-Life

Share to Headache

Share to Muscarinic Antagonists

Source

Identifiers

PMID: 19915829
DOI: 10.1007/s00228-009-0748-y

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-19915829-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The pharmacokinetic profile of fesoterodine 8 mg with daytime or nighttime dosing.PMID 19915829Read ↗

Population pharmacokinetics of the 5-hydroxymethyl metabolite of tolterodine after administration of fesoterodine sustained release tablet in Western and East Asian populations.Semantic proximity Read ↗

Comparison of pharmacokinetic variability of fesoterodine vs. tolterodine extended release in cytochrome P450 2D6 extensive and poor metabolizers.Semantic proximity Read ↗

Limitations of fexofenadine limited sampling strategy using plasma concentrations and partial area under the concentration-time curve to estimate transporter activity in healthy adults.Semantic proximity Read ↗

QT and QTc interval with standard and supratherapeutic doses of darifenacin, a muscarinic M3 selective receptor antagonist for the treatment of overactive bladder.Semantic proximity Read ↗

Oxycodone recycling: a novel hypothesis of opioid tolerance development in humans.Semantic proximity Read ↗

Evaluation of the Effect of Ritlecitinib on the Pharmacokinetics of Caffeine in Healthy ParticipantsSemantic proximity Read ↗

Lack of gender differences and large intrasubject variability in cytochrome P450 activity measured by phenotyping with dextromethorphan.Semantic proximity Read ↗

Effect of the inhibition of CYP3A4 or CYP2D6 on the pharmacokinetics and pharmacodynamics of oxycodone.Semantic proximity Read ↗

Effects of terbinafine and itraconazole on the pharmacokinetics of orally administered tramadol.Semantic proximity Read ↗

The effects of tramadol on static and dynamic pupillometry in healthy subjects--the relationship between pharmacodynamics, pharmacokinetics and CYP2D6 metaboliser status.Semantic proximity Read ↗

Single-point plasma or urine dextromethorphan method for determining CYP3A activity.Semantic proximity Read ↗

Absorption, distribution, metabolism and excretion of [14C]dexlansoprazole in healthy male subjects.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.